APVO Aptevo Therapeutics Inc

Price (delayed)

$1.64

Market cap

$2.96M

P/E Ratio

0.02

Dividend/share

N/A

EPS

$66.91

Enterprise value

-$2.63M

?
Relative Growth: Rel. Growth: 5
Relative Strength: Rel. Strength: 1
Relative Valuation: Rel. Valuation: 48
Relative Profitability: Rel. Profitability: 3

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company developing novel bispecific and trispecific immunotherapies for the treatment of cancer. Aptevo's pipeline includes two clinical candidates and multiple preclinical programs spanning ...

Highlights
The company's debt fell by 4.8% QoQ
APVO's EPS has surged by 185% since the previous quarter but it has dropped by 100% year-on-year
Aptevo Therapeutics's equity has decreased by 48% QoQ and by 7% YoY
The quick ratio has contracted by 38% from the previous quarter

Key stats

What are the main financial stats of APVO

APVO stock price

How has the Aptevo Therapeutics stock price performed over time
Intraday
-36.92%
1 week
-32.23%
1 month
-58.48%
1 year
-94.61%
YTD
-82.61%
QTD
-63.06%

Financial performance

How have Aptevo Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$26.89M
Net income
-$26.41M
Gross margin
N/A
Net margin
N/A
The company's operating income fell by 11% YoY
APVO's net income is down by 10% YoY

Price vs fundamentals

How does APVO's price correlate with its fundamentals

Growth

What is Aptevo Therapeutics's growth rate over time

Valuation

What is Aptevo Therapeutics stock price valuation
P/E
0.02
P/B
0.34
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
APVO's EPS has surged by 185% since the previous quarter but it has dropped by 100% year-on-year
APVO's P/B is 80% below its 5-year quarterly average of 2.7 but 8% above its last 4 quarters average of 0.5
Aptevo Therapeutics's equity has decreased by 48% QoQ and by 7% YoY

Efficiency

How efficient is Aptevo Therapeutics business performance
The return on equity has surged by 68% year-on-year
The company's return on invested capital fell by 48% YoY and by 11% QoQ
Aptevo Therapeutics's ROA has increased by 28% YoY

Dividends

What is APVO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for APVO.

Financial health

How did Aptevo Therapeutics financials performed over time
APVO's total assets is 71% higher than its total liabilities
The quick ratio has contracted by 38% from the previous quarter
The company's current ratio fell by 38% QoQ and by 8% YoY
The company's debt is 30% lower than its equity
The debt to equity has soared by 84% QoQ and by 8% YoY
Aptevo Therapeutics's equity has decreased by 48% QoQ and by 7% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.